Minghui Pharmaceutical Inc. Announces Positive Topline Results from Phase Ib/II Clinical Trial of MHB018A, a Subcutaneous Single-Domain IGF-1R Antibody, in Patients with Active, Moderate-to-Severe Thyroid Eye Disease (TED)
SHANGHAI, Oct. 22, 2024 /PRNewswire/ -- Minghui Pharmaceutical, Inc., a late-stage biopharmaceutical company dedicated to developing transformative medicines in immunology and oncology, today announced positive topline results from its Phase Ib/II clinical trial of MHB018A in patients with active TED. MHB018A is a novel subcutaneous VHH-Fc fusion protein that targets the insulin-like growth factor-1 receptor (IGF-1R), a validated...
World Psoriasis Day 2024: Psoriatic Disease and Family–Standing Together in Support and Understanding
STOCKHOLM, Oct. 22, 2024 /PRNewswire/ -- Each year on October 29th, the global community unites on World Psoriasis Day to raise awareness and advocate for progress in the fight against psoriatic disease. This year, the focus is on the profound impact of psoriatic disease on families, highlighted by the theme "Psoriatic Disease and Family." This chronic condition is a...
HELP Therapeutics announces FDA clearance of IND application for universal iPSC-derived HiCM-188 cell therapy for the treatment of end-stage heart failure
NANJING, China, Oct. 22, 2024 /PRNewswire/ -- HELP Therapeutics Co. Ltd, a clinical-stage cell therapy company, today announced that the U.S. Food and Drug Administration (FDA) has cleared its Investigational New Drug (IND) application for "Allogeneic Human iPSC-derived cardiomyocytes (HiCM-188) administered via intramyocardial injection during coronary artery bypass graft surgery." Heart failure (HF) is a significant public health issue,...
South Korean Mental Tech Startup DoctorPresso Publishes Study to Detect Depression from User-Generated Diary test data in International Journal
SEOUL, South Korea, Oct. 22, 2024 /PRNewswire/ -- Doctorpresso's study to detect depression from user-generated diary text data was published in the September 2024 issue of the Journal of Medical Internet Research (JMIR) in recognition of its excellence. JMIR noted the "new approach of Doctorpresso's digital mental health screening." DoctorPresso Mind Diary According...
Everest Medicines Announces Positive Results of Complete Chinese Subpopulation Data from the NEFECON® Global Phase 3 NefIgArd Clinical Trial Published in “Kidney 360” Magazine
SHANGHAI, Oct. 22, 2024 /PRNewswire/ -- Everest Medicines (HKEX 1952.HK, "Everest", or the "Company"), a biopharmaceutical company focused on the discovery, clinical development, manufacturing and commercialization of innovative therapeutics, today announced that the "Kidney 360" magazine has published the complete two-year subpopulation data from Chinese patients in the Phase 3 NefIgArd clinical trial of NEFECON® under the title "Efficacy...
【C.S】Cordyceps Sunshine Biotech Uplists to OTCQB, Aims for a Potential Nasdaq Uplisting
TAIPEI, Oct. 22, 2024 /PRNewswire/ -- Cordyceps Sunshine Biotech Holdings Co., Ltd. 【C.S】Group, recognized for its expertise in cultivating the rare medicinal fungus Taiwanofungus, native to Taiwan, has reached a significant milestone by uplisting to the OTCQB market. Top - 【C.S】Group 's flagship Taiwanofungus retail brand in Taiwan Aiming for a Future Nasdaq ListingThe...
A Comprehensive Introduction of the oneClick+ antigen platform
SHANGHAI, Oct. 22, 2024 /PRNewswire/ -- Sanyou Bio provides oneClick+ antigen one-stop solution, from antigen analysis to personalized preparation, to help tumor immunotherapy research and development. oneClick+ antigen platform is designed to provide high-quality annotation-related protein sequences, including protein amino acid sequences, isoelectric points, subcellular localization, structural domains, modification sites, and other properties, and to demonstrate non-redundant datasets, which...
Moleac Announces PT Ferron Par Pharmaceuticals as New Exclusive Partner in Indonesia
SINGAPORE, Oct. 21, 2024 /PRNewswire/ -- Moleac is excited to announce a significant milestone in the journey of NeuroAiD II MLC901 as PT Ferron Par Pharmaceuticals will become our exclusive partner in Indonesia effective Jan 1st 2025. We are immensely grateful for the fruitful 12-year partnership with PT Mersifarma Tirmaku Mercusana, and we sincerely thank them for their invaluable...
Datasea Announces the Closing of a $4.0 Million Private Offering, Primarily Funded by the Company’s CEO and Director
BEIJING, Oct. 21, 2024 /PRNewswire/ -- Datasea Inc. (NASDAQ: DTSS) ("Datasea" or the "Company"), a Nevada-based digital technology company focused on innovative high-tech acoustics and 5G AI multimodal digital technology, today announced that, as of October 15, 2024, the Company closed its Regulation S offering (the "Offering") with three investors, including its two largest shareholders, the Company's CEO...
Ping An Reports Steady Growth in Operating Profit, Robust Increases in Net Profit and Life & Health NBV in 9M 2024
HONG KONG and SHANGHAI, Oct. 21, 2024 /PRNewswire/ -- Ping An Insurance (Group) Company of China, Ltd. (hereafter "Ping An", or the "Group", HKEX: 2318 / 82318; SSE: 601318) today announced its results for the nine months ended September 30, 2024. In the first nine months of 2024, China's economy remained generally stable as it pursued high-quality development amidst...
